Inflammatory bowel disease is not normally associated with an increased risk of infections. However, immune modulating therapy entails a general higher risk for both bacterial and viral infections. This interrelation could be relevant in the current outbreak of COVID-19 where infected patients undergoing immune modulating therapy are thought to have increased risk for severe and complicated disease course. “Danish Society of Gastroenterology and Hepatology” has recommended to maintain the immune modulating therapy during the epidemy but endorse extra caution and awareness of preventing transmission.   Inflammatory bowel disease (IBD) is, despite the underlying dysregulation of the innate immune system, not necessarily associated with a higher risk ...

According to The European Crohn’s and Colitis Organization (ECCO), patients under immunosuppressive/immunomodulatory treatment are not in a significant increased risk of catching COVID-19. As the risk of severe infections is slightly higher in patients under immunosuppression therapies, it is expected that the same might occur in SARS-CoV-2 infections. But data from immunosuppressed patients and SARS-CoV-2 ...

#Seneste udgivelse

Almen praksis

Nr. 1 • februar 2020
14. årgang
  • Fokus på venøs tromboembolisme
  • Diabetes • Hjertesvigt
  • ADHD • Osteoporose
#

Almen praksis

Bo Gerdes

Bo Gerdes
praktiserende læge

Jens Georg Hansen

Jens Georg Hansen
overlæge, dr.med., speciallæge i almen medicin

  Tina Enevoldsen

Tina Enevoldsen
praktiserende læge